At Thermo Fisher Scientific, our top priority is the health and safety of our colleagues, and we continue to monitor their circumstances and provide targeted support for urgent needs.
Consistent with our Mission, the company, through direct donation and matching gifts, and our colleagues are donating more than $2 million towards relief efforts for Ukraine through organizations that include the International Committee for the Red Cross, International Rescue Committee and Save the Children.
In early March 2022, we announced a pause in non-critical healthcare sales and marketing operations due to supply chain disruption in Russia and Belarus. As the market conditions and supply challenges have continued to deteriorate over the past few months, we have made the decision to cease sales and manufacturing operations in Russia and Belarus moving forward. Our service delivery in Ukraine has been impacted and will ramp up once safe to do so.
We are committed to supporting colleagues who may be impacted by this decision. We will also monitor the ongoing situation and adjust accordingly.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
SOURCE Thermo Fisher Scientific
If you have any questions regarding this Press Release, please email us at email@example.com.